{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:42:29Z","timestamp":1784767349072,"version":"3.55.0"},"posted":{"date-parts":[[2025,11,13]]},"group-title":"Immunology","reference-count":78,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Postdoctoral Research Abroad Program from the National Science and Technology Council (NSTC), Taiwan","award":["NSTC-113-2917-I-564-017"],"award-info":[{"award-number":["NSTC-113-2917-I-564-017"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI174875"],"award-info":[{"award-number":["R01AI174875"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI174276"],"award-info":[{"award-number":["R01AI174276"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI155447"],"award-info":[{"award-number":["R01AI155447"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI137057"],"award-info":[{"award-number":["R01AI137057"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI153098"],"award-info":[{"award-number":["R01AI153098"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["P30AI060354"],"award-info":[{"award-number":["P30AI060354"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["DP1DA060607"],"award-info":[{"award-number":["DP1DA060607"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["DP2DA040254"],"award-info":[{"award-number":["DP2DA040254"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>Broadly neutralizing antibodies (bNAbs) are promising tools for HIV-1 treatment and prevention, due to their ability to mediate both Fab-dependent neutralization and Fc-dependent effector functions. While antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) have been implicated in antiviral activity, the extent to which these functions vary across bNAb epitopes, viral strains, and Fc region remains unclear. Here, we systematically evaluated twenty bNAbs targeting five distinct Env epitopes against a diverse panel of nine HIV-1 strains. We found that epitope specificity and Env sequence both critically influenced bNAb effector functions. CD4 binding site (CD4bs)- and V3 glycan-targeting bNAbs mediated the broadest and most potent ADCC and ADCP, while V1\/V2 apex-directed bNAbs preferentially induced ADCP. In contrast, MPER-targeting bNAbs triggered ADCC more selectively, and gp120\/gp41 interface-targeting bNAbs showed limited activity. Irrespective of binding epitope, different strains exhibited a broad range of effector function sensitivities. To investigate the impact of Fc modifications on this variability, we subclass-switched and introduced previously identified Fc mutations known to change Fc\u03b3 receptor affinity. Some of these mutations significantly boosted ADCC, while IgG3 subclass switching dramatically enhanced ADCP, even against highly resistant strains. Collectively, these results demonstrate that effector function is shaped by both antibody specificity and viral Env context and that rational Fc modification has the potential to improve antibody-based therapeutics against HIV.<\/jats:p>\n                <jats:sec>\n                  <jats:title>One Sentence Summary<\/jats:title>\n                  <jats:p>This study systematically evaluates the impact of bNAb epitope specificity, Env sequence, and Fc engineering on antibody-mediated effector functions.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.11.12.688078","type":"posted-content","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T22:05:36Z","timestamp":1763071536000},"source":"Crossref","is-referenced-by-count":1,"title":["Functional Activity of HIV-1 bNAbs Across Diverse Strains is Driven by Binding Site and Can be Enhanced Through Fc Engineering"],"prefix":"10.64898","author":[{"given":"Chia Jung","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vintus","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":false,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-9238","authenticated-orcid":false,"given":"Daniel","family":"Lingwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-3944","authenticated-orcid":false,"given":"Alejandro B.","family":"Balazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025111414201316000_2025.11.12.688078v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.22246"},{"key":"2025111414201316000_2025.11.12.688078v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/8394"},{"key":"2025111414201316000_2025.11.12.688078v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04797-9"},{"key":"2025111414201316000_2025.11.12.688078v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738"},{"key":"2025111414201316000_2025.11.12.688078v1.5","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000153"},{"key":"2025111414201316000_2025.11.12.688078v1.6","doi-asserted-by":"crossref","unstructured":"D. A. Spencer , M. B. Shapiro , N. L. Haigwood , A. J. Hessell , Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. Front Public Health 9, 690017 (2021).","DOI":"10.3389\/fpubh.2021.690017"},{"key":"2025111414201316000_2025.11.12.688078v1.7","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","article-title":"An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1","volume":"8","year":"2023","journal-title":"ACS Omega"},{"key":"2025111414201316000_2025.11.12.688078v1.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02968"},{"key":"2025111414201316000_2025.11.12.688078v1.9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00287-12"},{"key":"2025111414201316000_2025.11.12.688078v1.10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01141"},{"key":"2025111414201316000_2025.11.12.688078v1.11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00326-11"},{"key":"2025111414201316000_2025.11.12.688078v1.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1279"},{"key":"2025111414201316000_2025.11.12.688078v1.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008236117"},{"key":"2025111414201316000_2025.11.12.688078v1.14","first-page":"228r","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025111414201316000_2025.11.12.688078v1.15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01023-12"},{"key":"2025111414201316000_2025.11.12.688078v1.16","doi-asserted-by":"crossref","first-page":"e1009101","DOI":"10.1371\/journal.ppat.1009101","article-title":"RV144 HIV-1 vaccination impacts post-infection antibody responses","volume":"16","year":"2020","journal-title":"PLoS Pathog"},{"key":"2025111414201316000_2025.11.12.688078v1.17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.10.6596"},{"key":"2025111414201316000_2025.11.12.688078v1.18","doi-asserted-by":"crossref","unstructured":"T. H. Chu , E. F. Patz , M. E. Ackerman , Coming together at the hinges: Therapeutic prospects of IgG3. MAbs 13, 1882028 (2021).","DOI":"10.1080\/19420862.2021.1882028"},{"key":"2025111414201316000_2025.11.12.688078v1.19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126391"},{"key":"2025111414201316000_2025.11.12.688078v1.20","first-page":"228r","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025111414201316000_2025.11.12.688078v1.21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9662"},{"key":"2025111414201316000_2025.11.12.688078v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/nature06106"},{"key":"2025111414201316000_2025.11.12.688078v1.23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe3349"},{"key":"2025111414201316000_2025.11.12.688078v1.24","doi-asserted-by":"crossref","unstructured":"M. Phelps , A. B. Balazs , Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis. Front Immunol 12, 734304 (2021).","DOI":"10.3389\/fimmu.2021.734304"},{"key":"2025111414201316000_2025.11.12.688078v1.25","first-page":"e00634","article-title":"Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir","volume":"91","year":"2017","journal-title":"J Virol"},{"key":"2025111414201316000_2025.11.12.688078v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2020.03.001"},{"key":"2025111414201316000_2025.11.12.688078v1.27","doi-asserted-by":"crossref","unstructured":"O. Wilhelm , C. Jordan , H. Kek , M. M. Brunton-O\u2019Sullivan , L. Rikard-Bell , P. Ramanathan , A. W. Chung , P. Poumbourios , B. D. Wines , A. Jaworowski , A. C. Hearps , Afucosylated broadly neutralising antibodies targeting HIV envelope elicit enhanced NK cell-mediated cytotoxicity against HIV-infected CD4+ T cell and macrophage targets. J Leukoc Biol , qia f033 (2025).","DOI":"10.1093\/jleuko\/qiaf033"},{"key":"2025111414201316000_2025.11.12.688078v1.28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02194-14"},{"key":"2025111414201316000_2025.11.12.688078v1.29","doi-asserted-by":"crossref","unstructured":"T. Bruel , F. Guivel-Benhassine , S. Amraoui , M. Malbec , L. Richard , K. Bourdic , D. A. Donahue , V. Lorin , N. Casartelli , N. No\u00ebl , O. Lambotte , H. Mouquet , O. Schwartz , Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun 7, 10844 (2016).","DOI":"10.1038\/ncomms10844"},{"key":"2025111414201316000_2025.11.12.688078v1.30","first-page":"e02440","article-title":"Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies","volume":"91","year":"2017","journal-title":"J Virol"},{"key":"2025111414201316000_2025.11.12.688078v1.31","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12343"},{"key":"2025111414201316000_2025.11.12.688078v1.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005817"},{"key":"2025111414201316000_2025.11.12.688078v1.33","first-page":"e02325","article-title":"Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner","volume":"91","year":"2017","journal-title":"J Virol"},{"key":"2025111414201316000_2025.11.12.688078v1.34","doi-asserted-by":"crossref","unstructured":"S. W. de Taeye , T. Rispens , G. Vidarsson , The Ligands for Human IgG and Their Effector Functions. Antibodies (Basel ) 8, 30 (2019).","DOI":"10.3390\/antib8020030"},{"key":"2025111414201316000_2025.11.12.688078v1.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601197"},{"key":"2025111414201316000_2025.11.12.688078v1.36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000444"},{"key":"2025111414201316000_2025.11.12.688078v1.37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65708"},{"key":"2025111414201316000_2025.11.12.688078v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2016.02.001"},{"key":"2025111414201316000_2025.11.12.688078v1.39","doi-asserted-by":"crossref","unstructured":"S. I. Richardson , F. Ayres , N. P. Manamela , B. Oosthuysen , Z. Makhado , B. E. Lambson , L. Morris , P. L. Moore , HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol 12, 733958 (2021).","DOI":"10.3389\/fimmu.2021.733958"},{"key":"2025111414201316000_2025.11.12.688078v1.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008064"},{"key":"2025111414201316000_2025.11.12.688078v1.41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008083"},{"key":"2025111414201316000_2025.11.12.688078v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.04.050"},{"key":"2025111414201316000_2025.11.12.688078v1.43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02853-13"},{"key":"2025111414201316000_2025.11.12.688078v1.44","doi-asserted-by":"crossref","unstructured":"R. Liu , R. J. Oldham , E. Teal , S. A. Beers , M. S. Cragg , Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment. Antibodies (Basel ) 9, 64 (2020).","DOI":"10.3390\/antib9040064"},{"key":"2025111414201316000_2025.11.12.688078v1.45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"key":"2025111414201316000_2025.11.12.688078v1.46","first-page":"e01808","article-title":"Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV","volume":"95","year":"2020","journal-title":"J Virol"},{"key":"2025111414201316000_2025.11.12.688078v1.47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601473"},{"key":"2025111414201316000_2025.11.12.688078v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2020.04.022"},{"key":"2025111414201316000_2025.11.12.688078v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.106"},{"key":"2025111414201316000_2025.11.12.688078v1.50","first-page":"131","article-title":"Fc receptors as adaptive immunoreceptors","volume":"382","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"2025111414201316000_2025.11.12.688078v1.51","first-page":"e01255","article-title":"Differences in the Binding Affinity of an HIV-1 V2 Apex-Specific Antibody for the SIVsmm\/mac Envelope Glycoprotein Uncouple Antibody-Dependent Cellular Cytotoxicity from Neutralization","volume":"10","year":"2019","journal-title":"mBio"},{"key":"2025111414201316000_2025.11.12.688078v1.52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-569061"},{"key":"2025111414201316000_2025.11.12.688078v1.53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/COH.0000000000000796","article-title":"Engineering strategies of Anti-HIV antibody therapeutics in clinical development","volume":"18","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"key":"2025111414201316000_2025.11.12.688078v1.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.023"},{"key":"2025111414201316000_2025.11.12.688078v1.55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-bioeng-082721-024500","article-title":"Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations","volume":"24","year":"2022","journal-title":"Annu Rev Biomed Eng"},{"key":"2025111414201316000_2025.11.12.688078v1.56","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa377"},{"key":"2025111414201316000_2025.11.12.688078v1.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.030"},{"key":"2025111414201316000_2025.11.12.688078v1.58","doi-asserted-by":"crossref","unstructured":"J. T. Kim , T.-H. Zhang , C. Carmona , B. Lee , C. S. Seet , M. Kostelny , N. Shah , H. Chen , K. Farrell , M. S. A. Soliman , M. Dimapasoc , M. Sinani , K. Y. R. Blanco , D. Bojorquez , H. Jiang , Y. Shi , Y. Du , N. L. Komarova , D. Wodarz , P. A. Wender , M. D. Marsden , R. Sun , J. A. Zack , Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nat Commun 13, 121 (2022).","DOI":"10.1038\/s41467-021-27647-0"},{"key":"2025111414201316000_2025.11.12.688078v1.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.03.008"},{"key":"2025111414201316000_2025.11.12.688078v1.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.12.004"},{"key":"2025111414201316000_2025.11.12.688078v1.61","doi-asserted-by":"crossref","unstructured":"D. A. Spencer , B. S. Goldberg , S. Pandey , T. Ordonez , J. Dufloo , P. Barnette , W. F. Sutton , H. Henderson , R. Agnor , L. Gao , T. Bruel , O. Schwartz , N. L. Haigwood , M. E. Ackerman , A. J. Hessell , Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. Nat Commun 13, 662 (2022).","DOI":"10.1038\/s41467-022-28250-7"},{"key":"2025111414201316000_2025.11.12.688078v1.62","doi-asserted-by":"crossref","unstructured":"S. Xu , M. C. Carpenter , R. L. Spreng , S. D. Neidich , S. Sarkar , D. Tenney , D. Goodman , S. Sawant , S. Jha , B. Dunn , M. Juliana McElrath , V. Bekker , S. V. Mudrak , R. Flinko , G. K. Lewis , G. Ferrari , G. D. Tomaras , X. Shen , M. E. Ackerman , Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans. NPJ Vaccines 7, 90 (2022).","DOI":"10.1038\/s41541-022-00514-9"},{"key":"2025111414201316000_2025.11.12.688078v1.63","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/COH.0000000000000638","article-title":"Recent insights into Fc-mediated effector responses to HIV-1","volume":"15","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"key":"2025111414201316000_2025.11.12.688078v1.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.06.074"},{"key":"2025111414201316000_2025.11.12.688078v1.65","doi-asserted-by":"crossref","unstructured":"P. Rascle , G. Woolley , S. Jost , C. Manickam , R. K. Reeves , NK cell education: Physiological and pathological influences. Front Immunol 14, 1087155 (2023).","DOI":"10.3389\/fimmu.2023.1087155"},{"key":"2025111414201316000_2025.11.12.688078v1.66","doi-asserted-by":"crossref","unstructured":"C. Zhang , P. Oberoi , S. Oelsner , A. Waldmann , A. Lindner , T. Tonn , W. S. Wels , Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity. Front Immunol 8, 533 (2017).","DOI":"10.3389\/fimmu.2017.00533"},{"key":"2025111414201316000_2025.11.12.688078v1.67","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s42003-024-06975-z","article-title":"Characterization of macrophages associated with human skin models exposed to UV radiation","volume":"7","year":"2024","journal-title":"Commun Biol"},{"key":"2025111414201316000_2025.11.12.688078v1.68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122696599"},{"key":"2025111414201316000_2025.11.12.688078v1.69","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02868-14"},{"key":"2025111414201316000_2025.11.12.688078v1.70","first-page":"e0078923","article-title":"Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity","volume":"14","year":"2023","journal-title":"mBio"},{"key":"2025111414201316000_2025.11.12.688078v1.71","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3282"},{"key":"2025111414201316000_2025.11.12.688078v1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.09.001"},{"key":"2025111414201316000_2025.11.12.688078v1.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.07.006"},{"key":"2025111414201316000_2025.11.12.688078v1.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.022"},{"key":"2025111414201316000_2025.11.12.688078v1.75","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v5.i2.85"},{"key":"2025111414201316000_2025.11.12.688078v1.76","doi-asserted-by":"publisher","DOI":"10.1177\/1087057112465184"},{"key":"2025111414201316000_2025.11.12.688078v1.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(02)00482-7"},{"key":"2025111414201316000_2025.11.12.688078v1.78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608130103"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.11.12.688078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:01:01Z","timestamp":1768471261000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.11.12.688078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1101\/2025.11.12.688078","relation":{},"subject":[],"published":{"date-parts":[[2025,11,13]]},"subtype":"preprint"}}